Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2018

Prior Authorization Required for Brineura

For our commercial members, Harvard Pilgrim requires prior authorization for the medication Brineura, effective immediately. Brineura was approved by the Food and Drug Administration last year, and is used to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2).

To receive prior authorization for a commercial member, the following criteria must be met:

  • Diagnosis of CLN2 was confirmed by enzyme assay demonstrating a deficiency of tripeptidyl peptidase 1 (TPP1) enzyme activity or by genetic testing.
  • Brineura is prescribed to slow the loss of ambulation in symptomatic members.
  • Member is 3 years of age or older.
  • Brineura will be administered by, or under the direction of, a physician knowledgeable in intraventricular administration.

As a reminder, CVS Health–NovoLogix oversees our prior authorization program for medical drugs to optimize treatment outcomes and promote the safe and cost-effective use of these medications. To request authorization for Brineura, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882). For complete information, please refer to our new Brineura Medical Review Criteria and the associated prior authorization request form.

    Email this article to a colleague   

    Network Matters Archives

    Download printer-friendly version


    Sign Up for a Webinar on Our Genetic Testing Program


    Decreasing Preventable ED Visits and Hospital Readmissions

    Coverage of Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

    Prior Authorization Required for Brineura

    Prior Authorization Criteria Updated for Xgeva

    Mental Health Month and Alternative Health Benefits


    Reminder: Report Condition and Value Codes on Institutional Claims

    Update to Reimbursement of Codes With PC/TC Indicator of 3

    Reimbursement of 3D Rendering of Imaging Studies

    Correct Usage of Modifiers LT, RT, and 50


    Eric H. Schultz,
    President and Chief Executive Officer

    Robert Farias,
    Senior Vice President, Corporate Network Strategy

    Annmarie Dadoly,

    Joseph O'Riordan,

    Kristin Edmonston,
    Production Coordinator